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PhenylthioureaThe biosynthesis of pyoverdine, the major siderophore of Pseudomonas aeruginosa, is a well-organized process
involving a discrete number of enzyme-catalyzed steps. The final step of this process involves the PvdP tyrosi-
nase, which converts ferribactin into pyoverdine. Thus, inhibition of the PvdP tyrosinase activity provides an at-
tractive strategy to interfere with siderophore synthesis to manage P. aeruginosa infections. Here, we report
phenylthiourea as a non-competitive inhibitor of PvdP for which we solved a crystal structure in complex with
PvdP. The crystal structure indicates that phenylthiourea binds to an allosteric binding site and thereby interferes
with its tyrosinase activity.We further provide proofs that PvdP tyrosinase inhibition by phenylthiourea requires
the C-terminal lid region. This provides opportunities to develop inhibitors that target the allosteric site, which
seems to be confined to fluorescent pseudomonads, and not the tyrosinase active site. Furthermore, increases
the chances to identify PvdP inhibitors that selectively interfere with siderophore synthesis.
© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Nowadays, many bacteria have become resistant to multiple com-
mon antibiotics [1] by acquiring diverse resistancemechanisms [2]. An-
tibiotic resistance poses an increasing challenge to our healthcare
system. Therefore, new strategies to develop novel antibiotics are ur-
gently sought after. An alternative approach to design novel antibiotics
is by depriving bacteria from their supply of essentialmetals like, for ex-
ample iron. This metal acts as an essential cofactor in a number of bac-
terial enzymes and due to its limited supply it is one of the growth-
limiting factors [3]. Iron levels in the human body are tightly controlled
by many transport and storage mechanism thus leaving the free iron
concentrations below 1 μM [4]. To overcome this problem, bacteria
such as Pseudomonas aeruginosa secrete siderophores, which are high-
affinity chelating molecules that can capture iron at very low molarity
(Kf ~ 1024 M−1) [5], allowing the bacterium to compete for iron binding
with endogenous human iron binding proteins such as transferrin [6].l and Pharmaceutical Biology,
sity of Groningen, Antonius
. This is an open access article underThemajor siderophore of P. aeruginosa is pyoverdine [7]. Pyoverdine
binds ferric ion (Fe3+) to form a ferripyoverdine complex that can be
taken up via a specific receptor (FpvA) into the cell [8]. In the periplasm,
the Fe3+ is released and converted into Fe2+ by FpvC and FpvF and
taken up by FpvDE transporter into the cytoplasm [9]. Apart from iron
binding, pyoverdine is known as a virulence factor that autoregulates
the production of pyoverdine itself and also upregulates the production
of PrpL protease and exotoxin A, which are two other major virulence
factors of P. aeruginosa [10]. This key role indicates the potency to con-
trol infections caused by these bacteria through interfering with
pyoverdine synthesis. Indeed, several studies demonstrated that
P. aeruginosa pyoverdine-deficient mutants were not infectious [11,12].
The biosynthesis of pyoverdine involves at least 4 non-ribosomal
peptide synthetases (NRPs) and 10 other enzymes located in the cyto-
plasm and the periplasm of P. aeruginosa [8]. In the final step of the bio-
synthesis, at least five enzymes are involved: PvdM, PvdN, PvdO, PvdP
and PvdQ. A recent study reported that a biaryl nitrile compound,
ML318, can inhibit PvdQ in vitro and in a bacterial cell assay [13].
PvdQ is an Ntn-hydrolase located in the periplasm, which is also in-
volved in the biosynthesis of pyoverdine [14]. It means that the inhibi-
tion of pyoverdine biosynthesis through the inhibition of a pyoverdine
synthesizing enzyme can lead to inhibition of virulence and infection.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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the pyoverdine chromophore [15]. In addition, it has been reported
that a P. aeruginosa PvdP knock out mutant cannot produce pyoverdine
anymore [16]. Therefore, it is reasonable to presume that inhibition of
PvdP can block the production of pyoverdine. PvdP is a member of the
tyrosinase super family, but shows limited structural homology to eu-
karyotic tyrosinases.
In this study, we aim to identify novel small molecule inhibitors
of the PvdP tyrosinase by screening a collection of compounds that
have been reported to inhibit other members of the tyrosinase
super family. The screening provided phenylthiourea as a non-
competitive inhibitor of PvdP tyrosinase and crystallographic analy-
sis demonstrated phenylthiourea binding to an allosteric binding site
of PvdP. Crystallographic analysis also revealed that PvdP has an un-
usual C-terminal lid structure covering the active site. The data show
that phenylthiourea binding freezes the lid, thus interfering with en-
zymatic activity. Altogether, this indicates a novel mechanism to in-
terfere selectively with PvdP tyrosinase activity.
2. Materials and methods
2.1. Cloning and expression of PvdP
The PvdP gene was PCR amplified and cloned from P. aeruginosa
PA01 with additional N-terminal His·Tag® in pET-28a DNA-
Novagen (Merck & Co., USA) using standard protocol. Then, the plas-
mid pET-28a-PvdP was transformed into Escherichia coli BL21 (DE3)
competent cells. To produce the enzyme, we followed the published
protocol with a minor modification [15]. Ten milliliter overnight
preculture in LB media (~1.5 × 109 CFU/mL) was added into 1 L
2xTY media (both media supplemented with 50 μg/mL kanamycin).
Enzyme expression was induced with 0.1 mM isopropyl 1-thio-β-
D-galactopyranoside (IPTG) after OD600 of the culture reached 0.8
in a 200 rpm shaking incubator at 30 °C. After overnight incubation
in a 200 rpm shaking incubator at 20 °C the bacterial cells were har-
vested by centrifugation for 15 min at 5000g (Sorvall™ RC6, Thermo
Fisher Scientific, USA) at 4 °C.
2.2. Purification of PvdP
To purify the PvdP wildtype and PvdP without the C-terminal lid
covering the active site (PvdP-trunc) enzymes, we followed the
published protocol [15]. The final concentration was determined
based on the protein absorbance at 280 nm. The estimated protein
purity was higher than 95% assessed by Coomassie Brilliant Blue-
stained SDS-PAGE [17]. The both enzymes were concentrated to
5 mg/mL in 20 mM TRIS-HCl pH 8.0 buffer, aliquoted, snap-frozen
and stored in−80 °C until used for testing the compounds. For crys-
tallization, the buffer was exchanged via size-exclusion chromatog-
raphy using HiLoad 16/60 Superdex 75 column (GE Healthcare,
USA) pre-equilibrated with gel-filtration buffer (10 mM MMT
pH 8.0, 100 mM ammonium chloride). The purified enzyme eluted
as a single peak and was pooled and concentrated to 10 mg/mL at
4 °C.
2.3. Screening of mushroom tyrosinase inhibitors against PvdP activity
Commercially available mushroom tyrosinase inhibitors (Fig. S1)
were selected and their inhibitory activity on PvdP were determined.
The selection was based on the availability, diverse scaffolds and
their potency on mushroom tyrosinase. All chemical compounds
were analytical grade.
The conversion of 0.5 mM of L-tyrosine to dopachrome (475 nm) by
25 μg PvdP in 1 mL of 50 mM CHES (pH 8.0) and 250 μM CuSO4 in the
presence of 200 μM (diluted in 5% DMSO) tested compound was moni-
tored using an SPECTROstar® Omega microplate reader (BMG Labtech,Germany) on a 96 wells flat bottom transparent plate (VWR Interna-
tional, USA) for 30 min at 30 °C. The mixtures were incubated at 30 °C
for 5 min prior to monitoring. The percentage inhibition of each com-
pound was compared to the positive control which was determined
using the same assay asmentioned above. The IC50 value of potential in-
hibitors was determined based on a dose response curve of the percent
inhibition against PvdP. All of themeasurementswere done in triplicate.
2.4. Kinetic experiments with phenylthiourea
For the enzyme kinetic experiments, the reaction mixture consisted
of the same components as mentioned above but using different con-
centration of substrate and inhibitor. We used substrate at concentra-
tion 0.1, 0.2, 0.3, 0.4, 0.5, 0.7, 1.0 and 1.5 mM. Concentrations of the
inhibitor were arranged to comprise the IC50 value and analyzed
through Lineweaver-Burk plots. The obtained datawere plotted as 1/ve-
locity (1/V) vs 1/substrate concentration (1/[S]) based on Lineweaver-
Burk plots. TheMichaelis-Menten constant (Km) andmaximumvelocity
(Vmax) were also determined under the same reaction mixture.
2.5. Activity of phenylthiourea on PvdP-trunc
In order to measure the activity of the inhibitor on PvdP-trunc, a set
of reaction mixture as mentioned above was prepared. Phenylthiourea
300 μMwas incubated in themixture for 5 min prior to addition of sub-
strate and measurement. We used PvdP wildtype as a control using the
same concentration of phenylthiourea.
2.6. Buffer screening for crystallization of PvdP
In order to select the correct buffer for crystallization, a thermofluor-
based stability assay was performed [18,19]. We used SYPRO® Orange
dye (Invitrogen, USA) and followed a protocol by Lunev to perform
the assay [20].
2.7. Crystallization of PvdP bound to copper (PvdP-Cu) and PvdP bound to
copper and phenylthiourea (PvdP-Cu-PTU)
Screening for crystallization conditions for PvdP was performed
using a high throughput crystallization robot Crystal Gryphon (Art
Robbins Instrument, USA) and commercially available sparse-
matrix screening kits JCSG-plus™ and PACT premier™ (Molecular Di-
mensions, UK). All experiments were performed at 18 °C using the
sitting drop vapour diffusion technique in 96-well MRC plates (Mo-
lecular Dimensions, UK). Equal volumes (0.3 μL) of protein solution
and crystallization reagent were equilibrated in 50 μL of reservoir so-
lution. Medium size single crystals appeared within 7 days in various
drops containing Bis-Tris propane and PEG 3350. Further optimiza-
tion was performed by varying the precipitant concentration and
the pH. The optimal condition of the crystallization consists of
equal amount (1 μL) of 10 mg/mL PvdP and 20% (w/v) PEG 3350 in
0.1 M Bis-Tris Propane pH 7.5 at 18 °C. The PvdP-Cu and PvdP-Cu-
PTU crystals also grew within 7 days in the optimal condition men-
tioned above with the addition of 500 μM CuSO4 and 500 μM CuSO4
with 1 mM phenylthiourea, respectively.
2.8. Diffraction data collection and processing
PvdP crystalswere harvested usingmounted LythoLoops (Molecular
Dimensions, UK), transferred to cryo-buffer and subsequently flash-
frozen in−196 °C liquid nitrogen. The cryo-buffer was chosen based
on the estimation from Garman & Mitchell [21] and consisted of 20%
(w/v) PEG 3350 and 25% (v/v) glycerol in 0.1 M Bis-Tris Propane
pH 7.5. The x-ray diffraction data were collected at−173 °C at the P11
beamline of the Deutsches Elektronen-Synchrotron (Hamburg,
Germany). The intensity data were processed and scaled with XDS
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data collection statistics can be found in Table 1.2.9. Phasing and refinement
The structure of PvdP was solved using a SAD dataset collected
from a selenomethionine labelled crystal. An X-ray fluorescence
wavelength scan was performed and the result was analyzed using
CHOOCH. A clear peak for selenium was detected and a SAD dataset
was collected at the derived peak wavelength. The autosol wizard
[24] from the PHENIX package [25] could solve the structure and
subsequently auto-build around 80% of the residues in the structure
(R/Rfree = 28/36). After several cycles of manual model building
using COOT [26] combined with phased refinement using non-
crystallographic symmetry (NCS) restraints for all four molecules
in the asymmetric unit using Refmac5 [27] the initial model of ob-
tained from the selenomethionine data was transferred to the native
data set using PHASER [28], where the model building and refine-
ment was completed. The refined structure of apo-PvdP was used
to solve the structure of the PvdP-Cu and PvdP-Cu-PTU by molecular
replacement.
The quality of the final models and the geometrical restraints
were checked using Molprobity [29]. The coordinates and structure
factor amplitudes have been deposited in the Protein Data Bank
with accession codes 6RRR (PvdP), 6RRQ (PvdP-Cu) and 6RRP
(PvdP-Cu-PTU). Figures of the structures were created using
PyMOL 2.0.7 [30].Table 1
X-ray data collection and refinement statistics.
Semet PvdP PvdP PvdP-Cu PvdP-Cu-PTU
PDB ID – 6RRR 6RRQ 6RRP
Data
collection
Space group P1211 P1211 P1211 P1211
Cell
dimensions
a, b, c (Å) 93.20, 107.62,
108.30
44.16, 112.62,
100.26
50.72, 114.22,
100.91
50.239 113.88
100.577
α, β, γ (o) 90.00, 98,79,
90.00
90.00, 92,71,
90.00
90.00, 94.82,
90.00
90 94.335 90
Wavelength
(Å)
1.033200 1.033200 1.033200 1.033200
Resolution
(Å)
50.00–2.50 45.76–2.11 46.22–2.70 49.52–2.40
Rmerge (%) 8.16 (74.52) 14.9 (10.01) 7.6 (58.1)
〈I/σ (I)〉 13.01 (1.98) 11.97 (1.79) 10.81 (1.97)
Completeness 93.47 99.36 (97.22) 99,25 (99.02) 99.66 (98.86)
Multiplicity 4.5 (4.5) 3.7 (3.6) 3.8 (3.8)
Refinement
Resolution
(Å)
45.76–2.11 46.22–2.70 49.52–2.40
No. of
reflections
55,908 (5420) 31,331 (3143) 43,995 (4351)
Rwork/Rfree
(%)
17.17/21.93 19.51/25.39 20.11/25.47
No. of atoms
Protein 7641 7317 7465
Ligand/ion 12 10 24
Water 508 131 211
B-factors (Å)
Protein 35.22 50.69 47.95
Ligand/ion 48.93 52.68 77.25
Water 35.13 34.80 39.99
R.m.s.
deviations
Bond
lengths (Å)
0.014 0.011 0.016
Bond
angles (o)
1.76 1.47 1.933. Results and discussions
3.1. Inhibitory activity of the selected mushroom tyrosinase inhibitors on
PvdP
In this studywe aim to identify smallmolecule inhibitors of the PvdP
tyrosinase activity as a potential novel therapeutic option for the treat-
ment of bacterial infection caused by P. aeruginosa. To achieve this aim,
we tested mushroom tyrosine inhibitors on the enzymatic activity of
PvdP, because mushroom tyrosinase is one of the most investigated ty-
rosinases. Moreover, many inhibitors for mushroom tyrosinase have
been reported [31]. Screening of the collection of mushroom tyrosinase
inhibitors shows that some compounds inhibit PvdP tyrosinase activity
in a concentration-dependent manner. The inhibitory concentration
50% (IC50) values of those compounds were determined (Table 2).
Kojic acid is often used as reference compound and it inhibits mush-
room tyrosinase with micromolar potency. However, for PvdP tyrosine
activity the potency is proven to be limited to the high micromolar
range (IC50 = 0.75 ± 0.04 mM). Surprisingly, the other inhibitor, l-
mimosine, showed no inhibition on the enzymatic activity of PvdP.
Tropolone, kuraridin and piceatannol, which are stronger inhibitors on
the mushroom tyrosinase than kojic acid, also showed no inhibition
on PvdP. Similarly, the weak inhibitors of mushroom tyrosinase (stig-
masterol, morin hydrate, naringin) also showed no inhibition. It gave
an early indication that PvdP is a unique tyrosinase among the other ty-
rosinases. Interestingly, among the tested compounds, phenylthiourea,
a sulfur-containing compound proved to be the most potent inhibitor
of PvdP in this series (IC50 = 174.4 ± 8.9 μM).3.2. Kinetic experiments with phenylthiourea
Enzyme kinetics experiments for the inhibition of PvdP tyrosi-
nase activity by phenylthiourea were performed in order to charac-
terize the binding further. The Km value for L-tyrosine, which was
employed as a substrate, proved to be 1.36 mM, which was compara-
ble to previously reported values [15]. The results of the non-linear
curve fitting showed that phenylthiourea did not change the Km
values of PvdP towards its substrate L-tyrosine. However, a reduc-
tion of Vmax values was observed by increasing the phenylthiourea
concentration (Fig. 1A). The type of inhibition was then confirmed
by double reciprocal Lineweaver-Burk plots in the presence of differ-
ent concentration of phenylthiourea. The Lineweaver-Burk plots
clearly indicated phenylthiourea as a non-competitive inhibitor
(Fig. 1B). This information also gave another indication that PvdP is
different from other tyrosinases. Because on the previous reports
phenylthiourea has been reported as a competitive inhibitor of
mushroom tyrosinase (IC50= 0.55± 0.07 μM) [32] and sweet potato
tyrosinase (IC50 = 43 μM) [33].Table 2
Quantitative inhibitory activity of mushroom tyrosinase inhibitors against PvdP and
mushroom tyrosinase (IC50 ± SD in μM).
Compounds PvdP Mushroom tyrosinase (based on references)
Kojic acid 750 ± 43 16.67 ± 0.52 [33]
Tropolone N1000 1.2 [34]
Phenylthiourea 174.4 ± 8.9 0.55 ± 0.07 [35]
Stigmasterol N.I. N.I. [33]
L-mimosine N.I. 3.68 ± 0.02 [33]
Morin hydrate N.I. 81.3 ± 12.1 [36]
Kuraridine N.I. 0.6 [37]
Sesamol N.I. 1.6 [38]
Naringin N.I. N1000 [39]
Piceatannol N.I. 1.53 [40]
Quercetine N.I. N1000 [41]
N.I. = no inhibition; SD = standard deviation.
Fig. 1. The kinetic studies of phenylthiourea inhibitory activity on PvdP. (A)Michaelis-Menten; and (B) Lineweaver-Burkplots. The lineswith circle, square and triangle symbol correspond
to the concentrations of phenylthiourea at 0, 50, 100 μM, respectively. Data were presented as mean ± SD (n = 3).
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In this paper, we reported the structure of apo-PvdP solved by the
single-wavelength anomalous diffraction (SAD) method of
selenomethionine labelled PvdP (Semet PvdP). The structure of apo-
PvdP has been solved independently [34]. The two apo structures are
similar and refined to 2.1 Å resolution.
PvdP is known as a copper dependent enzyme [15]. Therefore, to get
insight of its active state at the molecular level, we co-crystallized PvdP
in the presence of Cu2+. In addition, to understand the interaction be-
tween phenylthiourea and PvdP, we did a co-crystallization of PvdP
with Cu2+ and phenylthiourea. The structure PvdP bound to Cu
(PvdP-Cu) and PvdP bound to Cu2+ and phenylthiourea (PvdP-Cu-Table 3
Tyrosinase structure comparison.
No Tyrosinase Metal
1
Agaricus bisporus Cu
2
A. bisporus Cu
3
Homo sapiens Zn
4
H. sapiens Zn
5
H. sapiens Zn
6
H. sapiens Zn
7
Bacillus megaterium Cu
8
B. megaterium Cu
9
B. megaterium Cu
10
B. megaterium Cu
11
B. megaterium Cu
12
Juglans regia Cu
13
Streptomyces castaneoglobisporus Cu
14
P. aeruginosa Zn
15
P. aeruginosa –
16
P. aeruginosa Cu
17
P. aeruginosa Cu
a Kojic acid bound not in the active site.
b Kojic acid bound in the active site.PTU) were solved by molecular replacement (MR) of the apo structure
to 2.7 Å and 2.4 Å resolution, respectively. The two latter structures
are novel and they provide interesting insight in the enzymatic mecha-
nism as discuss below. The structure of PvdP (6RRR), PvdP-Cu (6RRQ)
and PvdP-Cu-PTU (6RRP) has been deposited to the Protein Data
Bank. All of the PvdP crystals belong to space group P21 and were con-
firmed to have twomolecules in the asymmetry unit. The overall model
structures are in good quality as they have R andRfree factors below0,27.
A comparison of the crystal structure of PvdP (PDB ID = 6RRR) and
other tyrosinases also supported the facts above. Based on the sequence
alignment analysis (Clustal Omega, https://www.ebi.ac.uk/Tools), PvdP
is very distinct from other tyrosinases. The closest homolog of PvdP is ty-
rosinase of Bacillus megaterium (PDB ID = 3NQ5) having sequenceInhibitor PDB Lid covering active site
– 2Y9X No
Tropolone 2Y9W No
– 5M8L No
Tropolone 5M8O No
Kojic acid 5M8M No
Phenylthiourea 5M8S No
– 3NPY No
Kojic acida 3NQ1 No
SVF 5OAE No
Kojic acidb 5I38 No
p-Tyrosol 4P6T No
– 5CE9 No
– 1WXC No
– 6EYV No
– 6EYS Yes
– 6RRQ No
Phenylthiourea 6RRP Yes
216 J.P. Wibowo et al. / International Journal of Biological Macromolecules 146 (2020) 212–221identity of only 30,77%. Further investigation showed that PvdP is the only
tyrosinase with a C-terminal lid covering the active site while the other
tyrosinases do not have this lid (Table 3).
3.4. Structural analysis of PvdP structures
The crystal structure of apo-PvdP showed no copper-binding in
the active sites but putative binding sites were occupied by water
molecules. The active site is covered by a unique C-terminal lid
with Tyr531 residue blocking the substrate-binding pocket
(Fig. 2A). The crystal structure of PvdP-Cu clearly shows the presence
of two Cu2+ ions (CuA and CuB) in the active site. This structure dif-
fers from the previously published structure (PDB ID = 6EYV) since
they have Zn2+ ions in the active site instead of Cu2+. The CuA is tet-
rahedrally coordinated with His216, His220, His271 and CuB with
His375, His379, and His432. The distance between the two Cu2+Fig. 2. Comparison of the C-terminal lid among all of PvdP structures. (A) Crystal structure of ap
of PvdP-Cu (PDB ID = 6RRQ), the C-terminal lid is invisible in the presence of copper (orange
present again (green cartoon) together with copper ions in the active site (orange spheres). Th
in yellow. All figures were prepared with PyMOL 2.0.7 [30].ions is 4.1 Å. This structure shows that the C-terminal lid is non-
visible suggesting a random orientation of the lid, which means
that the active site is opened in the presence of Cu2+ (Fig. 2B). This
opening is due to displacement rather than to proteolytic cleavage.
This is confirmed by a LC-MS analysis where the two enzyme confor-
mations are shown to have the similar molecular weight (Fig. S2).
Apparently, this structural rearrangement has major consequences
to the PvdP crystal, since the mature and relatively big size apo crys-
tals were destroyed immediately when we soaked them with CuSO4.
This information is in concert with the observation that the
presence of Cu2+ ions is essential for the activity of PvdP [15]. It
suggests a mechanism in which opening of the lid in the presence
of Cu2+ giving an access to the substrate to reach the active site.
This control of access to the active side facilitated by Cu2+ ions
has not been reported on the other tyrosinase structures that
have been published.o PvdP (PDB ID=6RRR), the C-terminal lid is present (green cartoon) (B) Crystal structure
sphere) and (C) Crystal structure of PvdP-Cu-PTU (PDB ID = 6RRP), the C-terminal lid is
e six histidine residues of the active site are depicted in cyan, phenylthiourea is depicted
217J.P. Wibowo et al. / International Journal of Biological Macromolecules 146 (2020) 212–221The crystal structure PvdP-Cu-PTU gave us more insight into the in-
hibition mechanism of phenylthiourea on PvdP (Fig. 2C). In this struc-
ture, strong electron density is found in the active site, which
corresponds to the binding of copper ions at the expected locations in
the active site. In addition, phenylthiourea displays strong electron den-
sity in the binding pocket at the interface between the C-terminal do-
main and the N-terminal domain (Fig. 3A). It locates close to the end
part of the C-terminal lid covering the active site. Structural analysis in-
dicates the presence of hydrogen bonding andhydrophobic interactions
between phenylthiourea and the surrounding residues. The thioketone
group of phenylthiourea has two interactions with Trp320 and
Ser329 at a distance of 3.1 Å and 2.8 Å, respectively. The NH group is
in a distance of 3.4 Å to Arg53 and the NH2 group is slightly closer to
His333 at 3.2 Å (Fig. 3B). A structure comparison between apo PvdP
and PvdP-Cu-PTU structures indicates a very subtle rotation of the
beta-barrel domain towards the tyrosinase domain in each of the two
monomers upon binding of phenylthiourea.
The residues are part of the interface between the N-terminal β-
barrel domain (BBD) and the C-terminal tyrosinase domain (TYD) of
PvdP. This interface is mostly composed of helices α9, α10 and linkerFig. 3. Interaction of phenylthiourea with PvdP. (A) Representative 2Fo-Fc electron density o
domain, (B) phenylthiourea interacts with Arg53, Trp320, Ser329 and His333.sequences (residues 292–299) on the TYD site and a large portion of
the BBD domain. Five H-bonds stabilize the interface: one between
Asp56 and His333, one between Asp86 and Leu297 and three being
formed from Arg301 bridging to Leu104, Ala106, and Glu108 (Fig. 4A).
The binding of phenylthiourea to this interface increases its stability
by increasing the number of interactions, with three anchor points on
the TYD (Trp320, Ser329 and His333) and one on BBD (Arg53)
(Fig. 4B). Analysis of the B-factors revealed a decreased vibration mo-
tion of helix α10, from which Trp320, Ser329 and His333 are part of,
when the PTU-bound structure was compared to both apo and Cu-
bound structures (B-factor averages of 34.5, 47.8 and 48.4 respectively).
Similarly, helix α1, from which Arg53 is part of, presented a lower de-
gree of mobility (B-factors of 31.6, 41.6 and 43.6 for PTU-bound, apo
and Cu-bound respectively). A decreased vibration motion was also ob-
served in other regions of PTU-bound structure, including the active site
(B-factor average of 26.9 against 38.3 for apo and 41.5 for Cu-bound
structures). The comparison of B-factor averages of the complete struc-
tures revealed values of 32.7, 46.3 and 49.4 for PTU-bound, apo and Cu-
bound structures respectively. This indicates that the binding of phenyl-
thiourea to the interface between the two domains of PvdP reduces thef phenylthiourea is located in the interface between N-terminal domain and C-terminal
Fig. 4. A comparison structures of apo and Cu-PTU bound. (A) Apo PvdP structure has 5 H-bonds between TYD and BBD (B) the binding of phenylthiourea on PvdP increases interaction
between two domains, three anchor points on TYD (Trp320, Ser329, His333) and one anchor point on BBD (Arg53).
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tyrosinase activity by a novel allosteric mechanism.
Further structural analysis among PvdP and the other tyrosinase
structures showed interesting facts. The interface was not found in the
other tyrosinase structures and those residues are not conserved
among the other tyrosinases (Fig. S3). This is a new mode of binding
of a ligand to a tyrosinase, since the published structure of human tyros-
inase (PDB ID = 5M8S) [35] and sweet potato tyrosinase (PDB ID =
1BUG) [36] show phenylthiourea binding in the active site.
Interestingly, the C-terminal lid that is open in the PvdP-Cu structure
proves to be closed in the structure PvdP-Cu-PTU. As seen in our struc-
tures, the presence of phenylthiourea causes an ordering of C-terminallid covering the active site. The binding of phenylthiourea promotes
closing of the lid onto the PvdP active site. Presumably, due to phenyl-
thiourea binding the lid opening is somehow distorted and comes
back to its original position as observed in the apo-PvdP crystal struc-
ture. This lid prevents access of the substrate to the active site and, as
a result, implies that phenylthiourea acts as an allosteric inhibitor of
PvdP. Notably, the observed electron density of the lid in the PvdP-Cu-
PTU structure is not as strong as in the apo-PvdP structure, but it clearly
shows that the lid closes back onto the active site. Taken together, we
observed that binding of phenylthiourea promotes closure of the lid
even though the copper ions are present in the active site. This explains
that phenylthiourea acts as an inhibitor that limits the access of the
Fig. 5. Inhibition activity of 300 μM phenylthiourea on PvdP WT (wildtype) and PvdP-
trunc. An asterisk (*) indicates significant difference and n.s. indicates non-significant
differencebetween twogroups (Pb 0.05, Student's t-test). Datawere presented asmean±
SD (n = 3).
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well in line with non-competitive inhibition.
3.5. Inhibition mechanism of phenylthiourea on PvdP
To test this hypothesis, a mutant of PvdP without C-terminal lid de-
noted PvdP-trunc, was made to investigate the role of the C-terminal lid
in the mechanism of inhibition of PvdP by phenylthiourea. To obtain
thismutant, thirty-two amino acid residues of the C-terminal lidwere de-
leted. The mutation did not change the enzyme kinetic properties the ty-
rosinase activity of PvdP. The Km and Vmax values of the mutant were
determined under the same condition as for the native PvdP and showed
no significant difference between them (Table S1). This strongly suggests
that the residues of this lid are not involved in the catalytic activity.
The enzymatic activity of the mutant in the presence or absence
phenylthiourea was investigated. In support of our hypothesis phenyl-
thiourea acts as an inhibitor by binding to and stabilizing this lid, the as-
says demonstrated that phenylthiourea was unable to inhibit the
activity of PvdP-trunc. Indeed, the addition of phenylthiourea up to
300 μM to the enzymatic assay did not influence the activity of the mu-
tant (Fig. 5). In further support of the allosteric binding effect of phenyl-
thiourea on PvdP,we show that kojic acid, which is known to bind to the
mushroom tyrosinase active site, is able to inhibit both PvdP wildtype
and PvdP-trunc at equivalent levels (data not shown). The results indi-
cate that phenylthiourea inhibits PvdPwildtype but does not inhibit the
truncated PvdP. This supports the hypothesis that the C-terminal lid is
important for phenylthiourea mediated inhibition of PvdP tyrosinase
activity. The presence of the C-terminal lid in the PvdP-Cu-PTU crystal
structure regardless the presence of copper, and the activity of the lid-
truncated PvdP in the presence of phenylthiourea provides to our opin-
ion strong evidence that phenylthiourea actually decreases the terminal
lid flexibility and consequently inhibits PvdP tyrosinase activity.
Considering the importance of pyoverdine as iron transporter into
the bacterial cell, this system clearly represents a valuable therapeutic
target. Several studies to develop anti-virulence agents against
P. aeruginosa have been reported by targeting pyoverdine production
[37–39]. A study reported inhibition on PvdQ, a Ntn-hydrolase involved
in the biosynthesis pyoverdine, by small molecules showing inhibition
of pyoverdine production in the bacterial cell assay up to micromolar
range [13]. Another recent study reported that some compounds di-
rectly interact with pyoverdine thus reducing its pathogenicity and im-
proving the survival of Caenorhabditis elegans after infection with
P. aeruginosa [40]. Our finding indicates alternative strategy to develop
anti-virulent by targeting PvdP as a new approach in the same pathway.
3.6. Docking simulation between ferribactin and PvdP
Thedocking results showed the ferribactin bound to PvdP in the active
site and the tyrosine residue of ferribactin deeply buried in a distance 4.4
and 4.6 Å to the di-copper center (Fig. 6). Hydrogen interactions between
the ligand and the residues, to be found alongside the ferribactin struc-
ture, stretch between 2.8 and 3.5 Å (Table S2). The predicted binding af-
finities is in a range between−7.1 and−6.3 kcal/mol (Table S3) in 9
possible poses. This docking result gives us more information about
“open-close”mechanism of the active site via C-terminal lid movement.
Ferribactin is a large substrate in size, in physiological condition, this
mechanism guarantees ferribactin to be able to reach and bind to the ac-
tive site.
4. Conclusions
Based on our results, PvdP has a distinct structural architecture com-
pared to the other tyrosinases. PvdP has two domains (N-terminal and
C-terminal domain) and a special C-terminal lid covering the active
site. Phenylthiourea shows a non-competitive inhibitory activity
through rearrangement of the C-terminal lid. The discovery that PvdPcan be inhibited by non-competitive binding opens the possibility to de-
velop a specific compound against P. aeruginosa infection, that will not
inhibit other tyrosinases including human tyrosinases. Further optimi-
zation of drugs that exclusively inhibit the PvdP would be valuable.
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